Imaging the brain distribution of translocator protein (TSPO), a putative biomarker for glial
cell activation and neuroinflammation, may inform management of individuals infected with …

Purpose Over the past 20 years, neuroinflammation (NI) has increasingly been recognised
as having an important role in many neurodegenerative diseases, including Alzheimer's …

Neuroimaging of brain receptors began in the early 1980s. Now, some thirty-five years later,
PET imaging is still an expanding field of preclinical and clinical investigations. In addition to …

PET is used to image active inflammatory processes by targeting the translocator protein
(TSPO). In vitro, second-generation TSPO radioligands, such as PBR111, have been shown …

Microglial activation is a key pathological feature of Alzheimer's disease (AD). PET imaging
of translocator protein 18 kDa (TSPO) is a strategy to detect microglial activation in vivo …

The translocator protein (18 kDa)(TSPO), formerly known as the peripheral benzodiazepine
receptor (PBR), was originally identified as an alternate binding site for the central …

Spinal glial and proinflammatory cytokine actions are strongly implicated in pathological
pain. Spinal administration of the anti-inflammatory cytokine interleukin (IL)-10 abolishes …

Translocator protein 18 kDa (TSPO) is a biomarker of neuroinflammation.[11C] ER176
robustly quantifies TSPO in the human brain with positron emission tomography (PET) …

The 18-kDa translocator protein (TSPO), also known as the peripheral benzodiazepine
receptor, is a transmembrane protein in the outer mitochondrial membrane. TSPO has long …

Converging evidence points to the significant involvement of the immune system in autism
spectrum disorders (ASD). Positron emission tomography (PET) can quantify translocator …